全文获取类型
收费全文 | 21185篇 |
免费 | 2513篇 |
国内免费 | 615篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 571篇 |
妇产科学 | 271篇 |
基础医学 | 2366篇 |
口腔科学 | 496篇 |
临床医学 | 2629篇 |
内科学 | 3546篇 |
皮肤病学 | 424篇 |
神经病学 | 1544篇 |
特种医学 | 442篇 |
外国民族医学 | 1篇 |
外科学 | 1248篇 |
综合类 | 2809篇 |
现状与发展 | 1篇 |
一般理论 | 10篇 |
预防医学 | 2872篇 |
眼科学 | 293篇 |
药学 | 2486篇 |
29篇 | |
中国医学 | 1648篇 |
肿瘤学 | 551篇 |
出版年
2024年 | 114篇 |
2023年 | 609篇 |
2022年 | 1094篇 |
2021年 | 1510篇 |
2020年 | 1415篇 |
2019年 | 1200篇 |
2018年 | 1065篇 |
2017年 | 1155篇 |
2016年 | 1040篇 |
2015年 | 950篇 |
2014年 | 1386篇 |
2013年 | 1872篇 |
2012年 | 1172篇 |
2011年 | 1189篇 |
2010年 | 948篇 |
2009年 | 882篇 |
2008年 | 854篇 |
2007年 | 842篇 |
2006年 | 782篇 |
2005年 | 655篇 |
2004年 | 533篇 |
2003年 | 498篇 |
2002年 | 403篇 |
2001年 | 349篇 |
2000年 | 283篇 |
1999年 | 175篇 |
1998年 | 201篇 |
1997年 | 149篇 |
1996年 | 135篇 |
1995年 | 103篇 |
1994年 | 101篇 |
1993年 | 65篇 |
1992年 | 78篇 |
1991年 | 84篇 |
1990年 | 61篇 |
1989年 | 57篇 |
1988年 | 38篇 |
1987年 | 36篇 |
1986年 | 34篇 |
1985年 | 27篇 |
1984年 | 28篇 |
1983年 | 23篇 |
1982年 | 31篇 |
1981年 | 21篇 |
1980年 | 17篇 |
1979年 | 13篇 |
1978年 | 6篇 |
1976年 | 7篇 |
1974年 | 5篇 |
1968年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
3.
4.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
5.
6.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
7.
8.
9.
《Health & place》2019
The objective of this paper was to assess the link between premature mortality and a combination of neighbourhood contextual (environmental and health) and compositional (socioeconomic and demographic) characteristics. We statistically and spatially examined six environmental variables (ultrafine particles, carcinogenic and non-carcinogenic pollutants, pollution released to air, tree cover, and walkability index), six health service indicators (number health providers, breast, colorectal and cervical cancer screening uptake rates, student nutrition program uptake rates, and healthy food index), and eight socioeconomic indicators (total income, Gini coefficient, two age categories – below and above 40 years, proportion of females to males, visible minorities, Indigenous peoples, education, less than grade 9) among 140 neighbourhoods of the City of Toronto in Ontario (Canada). We applied principal component analysis to identify patterns and to reduce the number of explanatory variables into combined component axes that represent unique variation in these confounded and overlapping factors. We then applied regression analysis to model the relationship between the indices of enviro-health and socioeconomics and their potential relationship with premature mortality. Residual spatial analysis was used to investigate any remaining spatial structure (such as neighbourhoods with higher residual premature mortality rates). Neighbourhood Equity Index was correlated with our enviro-health and socioeconomic indices. Premature mortality within neighbourhoods was predicted by poor cancer screenings, pollution, lack of tree canopy, increased uptake of student nutrition programs and high walkability index. A negative association between premature mortality and pollution was associated low walkability index and presence of visible minorities within neighbourhoods. There was some unexplained residual spatial variation in our model of premature mortality - especially along the shores of Lake Ontario and in neighbourhoods with major highways or road corridors: premature mortality in Toronto neighbourhoods was higher than expected along highway-corridor neighbourhoods and shorelines. Our analysis revealed a significant relationship between neighbourhood contextual features – both environmental and health – and premature mortality, suggesting that these contextual components of neighbourhoods can predict rates of urban premature mortality in Toronto. 相似文献
10.
目的:研究乳腺癌细胞中转录调节因子c-Myb的表达对肺转移的影响及其分子机制。方法:构建c-Myb高表达的4T1乳腺癌细胞株,种植小鼠构建乳腺癌动物模型,检测实验动物肺转移情况,通过荷瘤抑制试验检测肺转移抑制效果。提取组织进行荧光PCR检测相关炎症因子的表达。利用Medisapiens数据库的生物信息学资源,对c-Myb和Ccl2的表达与乳腺癌患者的预后进行分析。结果:高表达c-Myb的荷瘤小鼠肺部转移灶明显减少,其中炎症相关因子表达受限。由数据库分析得出,c-Myb高表达患者生存期得以延长。结论:乳腺癌中c-Myb的表达能够通过炎症因子Ccl2抑制肺转移从而延长患者生存期。 相似文献